https://pharminent.com/market-access/market-access-intelligence-weekly-digest-september-11-2026/ 2026-09-11T20:32:24Z Pharminent en MARKET ACCESS INTELLIGENCE • Weekly Digest • September 11, 2026 2026-09-11T20:32:21Z Blog https://pharminent.com/fda-oncology-chief-sets-out-his-agenda-and-narrows-the-etcamah-precedent/ 2026-09-11T19:36:40Z Pharminent en FDA Oncology Chief Sets Out His Agenda — and Narrows the Etcamah Precedent 2026-09-11T19:36:34Z Blog https://pharminent.com/strategic-news-watch/strategic-news-watch-september-11-2026/ 2026-09-11T18:44:09Z Pharminent en Strategic News Watch • September 11, 2026 2026-09-11T18:44:04Z Blog https://pharminent.com/rare-disease-gene-therapy/rare-disease-gene-therapy-digest-september-10-2026/ 2026-09-10T21:14:51Z Pharminent en Rare Disease & Gene Therapy Digest • September 10, 2026 2026-09-10T21:14:48Z Blog https://pharminent.com/bayers-hyrnuo-wins-accelerated-frontline-approval-in-her2-mutant-nsclc-seven-months-behind-boehringer/ 2026-09-10T20:00:29Z Pharminent en Bayer's Hyrnuo Wins Accelerated Frontline Approval in HER2-Mutant NSCLC, Seven Months Behind Boehringer 2026-09-10T20:00:26Z Blog https://pharminent.com/strategic-news-watch/strategic-news-watch-september-10-2026/ 2026-09-10T17:08:21Z Pharminent en Strategic News Watch • September 10, 2026 2026-09-10T17:08:18Z Blog https://pharminent.com/bayers-hyrnuo-set-for-the-nsclc-frontlines-on-accelerated-fda-label-expansion/ 2026-09-10T18:48:48Z Pharminent en Bayer's Hyrnuo set for the NSCLC frontlines on accelerated FDA label expansion 2026-09-10T10:26:07Z Blog https://pharminent.com/hhs-appoints-permanent-fda-cber-cder-heads/ 2026-09-10T15:01:38Z Pharminent en HHS appoints permanent FDA CBER, CDER heads 2026-09-10T09:40:49Z Blog https://pharminent.com/solstice-oncology-secures-225m-to-drive-porustobarts-development-for-cancer-2/ 2026-09-10T18:16:39Z Pharminent en Solstice Oncology secures $225m to drive porustobart's development for cancer 2026-09-10T09:39:18Z Blog